Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC By Ogkologos - July 9, 2025 758 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Highlights the Importance of a Strong EU Commitment Towards Robust Science and Innovation Policies Following Meeting of EU Research Ministers on 29 May... Metastatic Breast Cancer: ESMO Clinical Practice Guideline EMA Recommends Extending Indications for Decitabine / Cedazuridine MOST POPULAR Immunotherapy Combination That Targets TIGIT Receptor Shows Promise in Non-Small Cell... December 19, 2022 2022 ASCO Annual Meeting Research Round Up: Advances in Treating Genitourinary... June 30, 2022 Significantly Longer PFS with First-line Pembrolizumab for MSI-H/dMMR mCRC December 3, 2020 Cancer in My Community: Striving to Lead People to Cancer Care... November 22, 2022 Load more HOT NEWS Efficacy, Safety, and Translational Data from Durvalumab Plus Ceralasertib in Advanced/Metastatic... ESMO Immuno-Oncology Congress 2024, Geneva, Switzerland, 11-13 December Veteran and His Loyal Dog Pass Away Within Hours Of Each... ESMO Launches Its Roadmap 2030 to Support Oncology Professionals and Foster...
